| Literature DB >> 21618057 |
Sadık Muallaoğlu1, Murat Koçer, Nilüfer Güler.
Abstract
Paclitaxel is highly active against a variety of solid tumors including breast lung, ovarian and head and neck cancer. Although peripheral neurotoxicity is well-known side effect, central nervous system (CNS) toxicity-related standard dose of paclitaxel is extremely uncommon, because paclitaxel dose not cross the blood-brain barrier and is not detectable in the cerebrospinal fluid. We present a patient with advanced stage breast carcinoma who developed acute and spontaneous resolving encephalopathy after weekly dose of paclitaxel. The patient did not have brain metastasis, or prior whole-brain irradiation, or any type of neurosurgery. Radiological imaging studies showed no abnormalities. CNS toxicity of paclitaxel should be kept in mind in patients without a previous history of brain metastasis or brain irradiation and even with low weekly doses.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21618057 DOI: 10.1007/s12032-011-9956-2
Source DB: PubMed Journal: Med Oncol ISSN: 1357-0560 Impact factor: 3.064